81.90 USD
▲+1.90+2.38%
盘后 82.00 +0.12%
2026-11-19
市值
$7.28B
市盈率
—
EPS
-2.78
股息率
—
52 周区间
37.01 – 93.95
成交量
2.52M
Beta
0.35
目标价
109.69
52W 低 37.0152W 高 93.95
价格走势
公司简介
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with...
关联新闻
- This Biotech Stock Is Up 291% From Its IPO Price. It's On Pace for a Record Closing High.
CG Oncology stock is on pace for a record closing high after ‘best case' Phase 3 trial results for its bladder cancer treatment.